WM Technology, Inc.

IRVINE, Calif.--(BUSINESS WIRE)--WM Technology, Inc. (OTCQX: MAPS) (“WM Technology” or the “Company”) today announced that it will release its financial results for the third quarter ended September 30, 2026 after market close on Monday, November 9, 2026. The Company previously announced that it would report results on November 5, 2026. The new date will allow additional time to complete the Company's quarterly review process.About WM TechnologyFounded in 2008, WM Technology, Inc. operates a lea.

IRVINE, Calif.--(BUSINESS WIRE)--WM Technology, Inc. (“WM Technology” or the “Company”) (OTC: MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced it will report financial results for its third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026. The financial results will be available on the Company's investor relations website at ir.weedmaps.com and on the SEC's website at www.sec.gov.About WM TechnologyFounded i.

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) --  Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest production batch of its MDMA (3,4-methylenedioxymethamphetamine) finished drug product. The capsules were manufactured at Optimi's GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed Phase 3 clinical trial of MDMA-assisted therapy in Canada (the “Proposed Phase 3 Trial”) for the treatment of post-traumatic stress disorder ("PTSD"), its next commercial export to Australia planned before the end of 2026, and a previously announced clinical trial in Israel in partnership with the Multidisciplinary Association for Psychedelic Studies ("MAPS").

WM Technology (NASDAQ: MAPS - Get Free Report) and Akamai Technologies (NASDAQ: AKAM - Get Free Report) are both technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations. Profitability This table compares WM Technology and Akamai